|
시장보고서
상품코드
2109022
유착 방지제 : 시장 동향, 경쟁 구도 및 시장 예측(2034년)Adhesion Barrier - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 전 세계 유착 방지제 시장은 2025년에 11억 달러 규모에 달할 것으로 예상되며, 2034년까지 20억 달러에 이를 것으로 전망됩니다.
- 2026년부터 2034년까지의 예측 기간 동안, 이 시장은 연평균 성장률(CAGR) 6.9%로 확대될 것으로 예측됩니다. 이러한 배경에는 복부, 골반, 부인과, 척추 수술 건수 증가, 유착 관련 합병증에 대한 외과의사와 환자의 인식 제고, 히알루론산 및 합성 고분자 기반 배리어 기술에 대한 임상적 근거의 축적, 그리고 지혈과 유착 예방 기능을 겸비한 다기능 제품의 도입 등이 있습니다.
- 제품 유형별로는 2025년에 필름 및 멤브레인 배리어 부문이 39%의 점유율을 차지하며 유착 방지 배리어 시장을 주도했습니다.
- 소재별로는 2025년에 히알루론산 및 셀룰로오스계 배리어 부문이 44%의 점유율을 차지하며 유착 방지 배리어 시장을 주도했습니다.
- 용도별로는 2025년에 부인과 수술 부문이 34%의 점유율을 차지하며 유착 방지 배리어 시장을 주도했습니다.
- 최종 사용자별로는 2025년에 병원 부문이 71%의 점유율을 차지하며 유착 방지 배리어 시장을 주도했습니다.
- 2025년 시점에서 북미는 유착 방지제 시장에서 41%라는 최대 점유율을 차지했으나, 2034년까지는 아시아태평양이 가장 빠른 성장세를 보일 것으로 예측됩니다.
유착 방지제는 수술 중에 적용되는 의료기기로, 치유 기간 동안 손상된 조직 표면을 분리하고, 수술 후 장기나 조직 사이에 형성되는 흉터 조직의 섬유성 띠인 수술 후 유착의 발생률, 범위 및 중증도를 완화하는 역할을 합니다. 여기에는 박스터(Baxter)의 Seprafilm과 같은 히알루론산 및 카르복시메틸셀룰로오스(HA/CMC) 필름, 존슨앤존슨 메드테크(Johnson & Johnson MedTech)의 Interceed 및 Intercoat와 같은 산화 재생 셀룰로오스 장벽, 박스터사의 Adept와 같은 이코덱스트린계 유착 저감 용액, Fziomed사의 Oxiplex 및 SprayShield 시리즈와 같은 이원 중합체(카르복시메틸셀룰로오스·폴리에틸렌옥사이드) 겔 및 스프레이, Integra LifeSciences사의 DuraGen Plus와 같은 콜라겐계 경막 유착 방지 매트릭스, Anika Therapeutics가 개발하고 Nordic Pharma사가 판매하는 Hyalobarrier 등의 히알루론산 젤, PlantTec Medical의 4DryField PH 등의 전분계 분말 및 겔 배리어, 그리고 Biom'Up의 Cova CARD나 MAST Biosurgery의 CardioWrap 등의 심혈관 외과용 생체 흡수성 합성 필름 및 콜라겐 필름 등이 있습니다. 이 시장은 산부인과, 일반·복부외과, 정형외과·척추외과, 심혈관외과, 신경외과, 비뇨기과 수술 분야의 용도를 포괄하고 있습니다.
유착 방지제 시장의 주요 성장 촉진요인
- 수술 중 유착 예방의 주요 수요 기반이 되는 복부, 골반, 산부인과 및 척추 수술의 전 세계 건수 증가.
- 장폐색, 만성 골반통, 불임증 등 유착과 관련된 합병증의 발생률, 비용 및 유병률에 대한 외과의사와 환자의 인식이 높아지고 있습니다.
- 히알루론산, 셀룰로오스 및 합성 고분자를 이용한 장벽 기술에 대한 임상적 근거가 확대되고 있으며, 이는 진료 지침에의 채택 및 병원의 구매 결정을 뒷받침하고 있습니다.
- 지혈과 유착 예방을 한 번의 시술로 겸비한 다기능 제품의 도입으로 수술 워크플로우가 간소화되고 있습니다.
- 복부 및 골반 수술의 재수술·수정 수술 발생률이 높아지면서, 이에 따라 유착 관련 합병증 위험이 높은 환자군이 증가하고 있습니다.
- 저침습 및 복강경 수술 기술의 채택이 증가함에 따라, 젤이나 스프레이 형태의 장벽제가 적용 가능한 수술 범위가 확대되고 있습니다.
- 재입원율 및 재수술율을 낮추고, 가치 기반 의료의 목표를 지원하는 수술 보조 제품에 대한 병원 및 외래수술센터(ASC)의 투자가 증가하고 있습니다.
유착 방지제 시장의 성장에 기여하는 요인
시장 성장 촉진요인
복부, 골반, 부인과, 척추 수술 건수 증가
유착 방지제 시장의 근본적인 촉진요인은 복부, 골반, 부인과 및 척추 수술 건수가 전 세계적으로 지속적으로 증가하고 있다는 점입니다. 이러한 수술은 모두 수술 후 유착 형성이라는 중대한 위험을 수반합니다. 박스터(Baxter)사를 비롯한 제조업체들이 인용한 연구에 따르면, 개복 수술을 받은 환자의 최대 93%에서 유착이 발생하며, 유착과 관련된 합병증으로 인해 미국에서만 연간 20억 달러 이상의 외과적 비용이 발생하는 것으로 추정됩니다. 고령화의 진행과 부인과 질환·대장 질환의 유병률 상승에 따라 자궁 적출술, 근종 적출술, 장 절제술, 제왕절개, 그리고 요추 수술 건수가 증가함에 따라, 보조적 유착 방지제의 사용 대상이 되는 환자층도 그에 따라 확대되고 있습니다. 외과의사들은 고위험 수술, 특히 복부 및 골반 수술의 재수술 시 유착 방지제를 일상적인 보조 수단으로 점점 더 많이 도입하고 있으며, 이에 따라 예측 기간 동안 유착 방지제 제품에 대한 수요가 유지될 것으로 전망됩니다.
유착 관련 합병증 및 비용에 대한 인식 제고
수술 후 유착이 초래하는 임상적·경제적 부담에 대한 외과의사 및 의료 시스템의 인식 제고는 유착 방지제 채택을 강력히 뒷받침하는 요인이 되고 있습니다. 유착은 소장 폐색, 만성 골반통, 이차성 불임의 주요 원인이며, 재수술 시 수술의 복잡성, 소요 시간 및 합병증 위험을 크게 높입니다. 이러한 부담에도 불구하고, 발표된 연구에 따르면 복부·골반 수술을 받는 환자 중 유착의 위험이나 예방 조치에 대해 설명을 듣는 사람은 극히 일부에 불과하며, 인식이 높아짐에 따라 도입 여지가 충분함이 밝혀졌습니다. 병원과 외과의사들이 유착과 관련된 재입원 및 재수술로 인한 2차 비용을 점점 더 인식함에 따라, 고위험 수술에서 예방적 보조 수단으로서의 유착 방지제 사용은 확대될 것으로 예상되며, 예측 기간 동안 수요가 유지될 전망입니다.
시장 성장 억제요인
유착 방지 장벽 시장은 성장을 억제하는 몇 가지 상호 연관된 제약에 직면해 있습니다. 가장 큰 요인은 재수술이나 장폐색과 같은 임상적으로 중요한 유착 관련 결과의 실제 감소와 관련하여, 각 장벽 기술 간에 일관성이 없고 경우에 따라 상충되는 임상적 증거가 존재한다는 점입니다. 이로 인해 일부 시장에서는 지침에 따른 권고 강도나 보험 급여 지원이 제한되고 있습니다. 특정 필름형 장벽과 관련된 염증 반응 보고나, 혈액 및 체액이 존재할 경우의 유효성 저하 등 제품 고유의 안전성 우려가 있어, 환자를 신중하게 선별하고 수술 기법에 주의를 기울여야 하며, 오염된 수술 부위나 출혈이 있는 수술 부위에서의 사용이 제한될 가능성이 있습니다. 또한, 필름, 젤, 스프레이 계열의 장벽 제품은 표준 수술 기법에 비해 단가가 비교적 높기 때문에 비용에 민감한 의료 현장이나 자원이 제한된 의료 현장에서의 도입이 제약받고 있습니다. 현재 복부·골반 수술 대상 환자 중 유착의 위험이나 예방 조치에 대해 설명을 듣고 있는 환자는 극히 일부에 불과하며, 이는 유착 방지제의 사용이 표준 수술 프로토콜에 일상적으로 포함되지 않고 있음을 반영합니다. 규제 및 보험 급여 체계는 지역이나 제품 범주에 따라 크게 다르며, Fziomed사가 2025년에 승인받은 요추 통증 완화 같은 새로운 적응증에 대한 보험 적용 결정이 광범위한 임상 현장에서 보급으로 이어지기까지는 시간이 걸립니다. 이러한 요인들이 복합적으로 작용하여 도입 속도가 완만해지고 있으며, 공급업체는 성장을 유지하기 위해 일관되고 수술별로 특화된 임상적 유효성과 양호한 의료경제적 성과를 입증해야 합니다.
자주 묻는 질문
목차
제1장 유착 방지제 시장 : 서론
제2장 유착 방지제 시장 : 주요 요약
제3장 유착 방지제 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 유착 방지제 시장 : 평가
제8장 유착 방지제 시장 : 경쟁 구도
제9장 유착 방지제 시장 : 스타트업의 자금조달 및 투자 동향
제10장 유착 방지제 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.13Adhesion Barrier Market Summary
Overview:
- The global adhesion barrier market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.0 billion by 2034.
- The market is expected to expand at a CAGR of 6.9% during the forecast period 2026-2034, supported by the rising volume of abdominal, pelvic, gynecological, and spine surgeries, growing surgeon and patient awareness of adhesion-related complications, the expanding clinical evidence base for hyaluronic acid and synthetic polymer barrier technologies, and the introduction of multifunctional products that combine hemostasis with adhesion prevention.
- By product type, the film and membrane barriers segment dominated the adhesion barrier market with a 39% share in 2025.
- By material, the hyaluronic acid and cellulose-based barriers segment dominated the adhesion barrier market with a 44% share in 2025.
- By application, the gynecological surgery segment dominated the adhesion barrier market with a 34% share in 2025.
- By end-user, the hospitals segment dominated the adhesion barrier market with a 71% share in 2025.
- North America accounted for the largest share of the adhesion barrier market at 41% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.
Adhesion barriers are medical devices applied intraoperatively to separate injured tissue surfaces during the healing period and reduce the incidence, extent, and severity of postoperative adhesions, the fibrous bands of scar tissue that form between organs and tissues following surgery. The scope encompasses hyaluronic acid and carboxymethylcellulose (HA/CMC) films such as Seprafilm from Baxter, oxidized regenerated cellulose barriers such as Interceed and Intercoat from Johnson & Johnson MedTech, icodextrin adhesion reduction solution such as Adept from Baxter, dual-polymer carboxymethylcellulose-polyethylene oxide gels and sprays such as the Oxiplex and SprayShield family from Fziomed, collagen-based dural adhesion barrier matrices such as DuraGen Plus from Integra LifeSciences, hyaluronic acid gels such as Hyalobarrier from Anika Therapeutics and distributed by Nordic Pharma, starch-based powder and gel barriers such as 4DryField PH from PlantTec Medical, and bioresorbable synthetic and collagen films for cardiovascular surgery such as Cova CARD from Biom'Up and CardioWrap from MAST Biosurgery. The market spans applications in gynecological, general and abdominal, orthopedic and spine, cardiovascular, neurological, and urological surgery.
Adhesion Barrier Market Key Growth Drivers
- Rising global volume of abdominal, pelvic, gynecological, and spine surgeries that create the primary demand base for intraoperative adhesion prevention.
- Growing surgeon and patient awareness of the incidence, cost, and morbidity of adhesion-related complications, including bowel obstruction, chronic pelvic pain, and infertility.
- Expanding clinical evidence base for hyaluronic acid, cellulose, and synthetic polymer barrier technologies that supports guideline inclusion and hospital purchasing decisions.
- Introduction of multifunctional products that combine hemostasis and adhesion prevention in a single application, simplifying surgical workflow.
- Rising incidence of repeat and revision abdominal and pelvic surgery, which increases the population of patients at elevated risk of adhesion-related morbidity.
- Increasing adoption of minimally invasive and laparoscopic surgical techniques that expand the addressable procedure base for gel and spray-format barriers.
- Growing hospital and ambulatory surgical center investment in surgical adjuncts that reduce readmission and reoperation rates and support value-based care objectives.
Key Companies in Adhesion Barrier Market
The leading participants in the adhesion barrier market include the following:
- Baxter International Inc.
- Fziomed, Inc.
- Integra LifeSciences Holdings Corporation
- Medical Devices Business Services, Inc. (Johnson & Johnson MedTech)
- Anika Therapeutics, Inc.
- PlantTec Medical GmbH
- Biom'Up SA
- MAST Biosurgery USA, Inc.
- Nordic Pharma
- Actamax Surgical Materials, LLC
Factors Contributing to the Growth of the Adhesion Barrier Market
Market Drivers
Rising Volume of Abdominal, Pelvic, Gynecological, and Spine Surgeries
The foundational driver of the adhesion barrier market is the sustained global growth in the volume of abdominal, pelvic, gynecological, and spine surgical procedures, each of which carries a meaningful risk of postoperative adhesion formation. Studies cited by manufacturers including Baxter indicate that up to 93% of patients develop adhesions following laparotomy, and adhesion-related complications drive an estimated USD 2 billion or more in annual surgical costs in the United States alone. As the volume of hysterectomy, myomectomy, bowel resection, cesarean section, and lumbar spine procedures grows with the aging population and the rising prevalence of gynecological and colorectal conditions, the population of patients eligible for adjunctive adhesion barrier use expands correspondingly. Surgeons increasingly incorporate adhesion barriers as a routine adjunct in high-risk procedures, particularly repeat abdominal and pelvic surgery, sustaining demand for adhesion barrier products across the forecast period.
Growing Awareness of Adhesion-Related Morbidity and Cost
Growing surgeon and health system awareness of the clinical and economic burden of postoperative adhesions is a powerful driver of adhesion barrier adoption. Adhesions are a leading cause of small bowel obstruction, chronic pelvic pain, and secondary infertility, and they substantially increase the complexity, duration, and risk of complications in reoperative surgery. Despite this burden, publicly cited studies indicate that only a minority of patients undergoing abdominopelvic surgery are counseled about adhesion risk or prevention options, indicating substantial headroom for adoption as awareness grows. As hospitals and surgeons increasingly recognize the downstream cost of adhesion-related readmission and reoperation, the use of adhesion barriers as a preventive adjunct in high-risk procedures is expected to expand, sustaining demand across the forecast period.
Market Restraints
The adhesion barrier market faces several interrelated restraints that temper its growth. The foremost is the inconsistent and, in some cases, contradictory clinical evidence across barrier technologies regarding real-world reduction in clinically meaningful adhesion-related outcomes such as reoperation and bowel obstruction, which limits the strength of guideline recommendations and reimbursement support in several markets. Product-specific safety considerations, including reports of inflammatory response associated with certain film barriers and reduced efficacy in the presence of blood or body fluid, require careful patient selection and surgical technique and can limit use in contaminated or bleeding surgical fields. The relatively high per-unit cost of film, gel, and spray barrier products relative to standard surgical technique constrains adoption in cost-sensitive and lower-resource healthcare settings. Only a minority of eligible abdominopelvic surgery patients are currently counseled about adhesion risk and prevention options, reflecting limited routine integration of adhesion barrier use into standard surgical protocols. Regulatory and reimbursement pathways vary considerably by geography and by product category, and coverage determinations for newer indications, such as Fziomed's 2025 authorization for lumbar spine pain reduction, will take time to translate into broad clinical uptake. Together, these factors moderate the pace of adoption and require vendors to demonstrate consistent, procedure-specific clinical benefit and favorable health-economic outcomes to sustain growth.
Adhesion Barrier Market Segment Analysis
The global adhesion barrier market is segmented by product type (film and membrane barriers, gel barriers, solution and liquid barriers, and powder and spray barriers), by material (hyaluronic acid and cellulose-based barriers, synthetic polymer-based barriers, collagen-based barriers, and starch and polysaccharide-based barriers), by application (gynecological surgery, general and abdominal surgery, orthopedic and spine surgery, cardiovascular surgery, neurological surgery, urological surgery, and others), by end-user (hospitals, ambulatory surgical centers, specialty clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Product Type
Dominant Subsegment: Film and Membrane Barriers.
The film and membrane barriers category is expected to dominate the market. The film and membrane barriers segment accounted for a 39% share of the adhesion barrier market in 2025. Film and membrane barriers, including Baxter's Seprafilm HA/CMC membrane, Johnson & Johnson MedTech's Interceed oxidized regenerated cellulose barrier, Integra LifeSciences' DuraGen Plus collagen matrix, and Biom'Up's Cova CARD cardiac film, are the leading product category because they provide a physical, mechanically stable barrier that is straightforward to place precisely over the surgical site during open procedures and because they benefit from the longest-established and most extensive clinical evidence base among adhesion barrier formats. The dominance of the segment reflects the breadth of established, widely distributed film products across abdominopelvic, neurological, and cardiac surgery, and the preference of surgeons for a barrier that remains in place without migration during open laparotomy and sternotomy procedures. While gel, solution, powder, and spray barriers are substantial and, in the case of gel and spray formats compatible with laparoscopic delivery, faster-growing categories, the clinical familiarity, precision of placement, and evidence depth of film and membrane barriers sustain the leadership of the segment across the forecast period.
By Material
Dominant Subsegment: Hyaluronic Acid and Cellulose-Based Barriers.
The hyaluronic acid and cellulose-based barriers category is expected to dominate the market. The segment accounted for a 44% share of the adhesion barrier market in 2025. Hyaluronic acid and cellulose-based barriers, including Baxter's Seprafilm and Sepraspray HA/CMC products, Johnson & Johnson MedTech's Interceed and Intercoat oxidized regenerated cellulose barriers, and Anika Therapeutics' Hyalobarrier hyaluronic acid gel distributed by Nordic Pharma, are the leading material category because hyaluronic acid and cellulose polymers are naturally resorbable, biocompatible, and supported by the deepest body of comparative clinical evidence among adhesion barrier materials. The dominance of the segment reflects the multi-decade commercial history and regulatory approval breadth of HA/CMC and oxidized regenerated cellulose technologies across the United States, Europe, and Asia. While synthetic polymer-based barriers such as Fziomed's dual-polymer CMC-PEO gels and Baxter's icodextrin-based Adept solution, collagen-based barriers, and starch-based barriers such as PlantTec Medical's 4DryField PH are significant and, in several cases, faster-growing categories, the evidence depth and regulatory maturity of hyaluronic acid and cellulose-based barriers sustain the leadership of the segment across the forecast period.
Adhesion Barrier Market Region Analysis
Dominant Region: North America
North America accounted for a 41% share of the global adhesion barrier market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of leading manufacturers including Baxter, Fziomed, Integra LifeSciences, and Johnson & Johnson MedTech, the high volume of abdominal, pelvic, and spine surgery, advanced reimbursement and hospital purchasing infrastructure, and the depth of FDA premarket approval and de novo authorization activity, exemplified by Fziomed's November 2025 FDA authorization of Oxiplex gel for lumbar spine surgery. The United States is the largest national market, supported by the concentration of adhesion barrier manufacturers, comprehensive hospital distribution networks, and growing surgeon awareness of adhesion-related morbidity and cost. The concentration of vendors, regulatory leadership, and surgical volume reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding and modernizing its surgical infrastructure, increasing the volume of gynecological, abdominal, and spine surgery, and adopting adhesion barrier products from a growing base. China, Japan, and India are the principal national markets, supported by the construction and modernization of hospitals, the expansion of laparoscopic and minimally invasive surgical capacity, and the presence of Baxter's Seprafilm, which maintains commercial distribution in Japan, China, and South Korea. As hospitals build surgical capacity and as awareness of adhesion-related complications increases, the region increases its adoption of adhesion barrier products from a growing base, positioning Asia-Pacific as the fastest-growing regional market.
Regional Commentary
North America
North America leads the market, supported by the concentration of leading vendors, high surgical volume, and advanced regulatory and reimbursement infrastructure. The United States dominates the region through its concentration of manufacturers and hospital distribution networks and through continued FDA authorization of new indications.
Europe
Europe is a substantial market shaped by CE marking pathways, established reimbursement for surgical adjuncts, and the presence of vendors including Baxter, Johnson & Johnson MedTech, PlantTec Medical, Biom'Up, and Nordic Pharma. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and PlantTec Medical's starch-based 4DryField PH platform is anchored in the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by hospital modernization, the expansion of laparoscopic and minimally invasive surgical capacity, and the growth of gynecological, abdominal, and spine surgery volumes across China, Japan, and India.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as surgical infrastructure expands, though adoption varies by market and remains concentrated in leading private and academic hospitals.
Adhesion Barrier Market Competitive Landscape
The global adhesion barrier market is classified as Moderately Consolidated. A group of established medical technology companies holds a substantial share of the market through comprehensive surgical adjunct portfolios and long-standing hospital relationships, while specialist vendors compete on differentiated single-technology platforms across gel, spray, and starch-based formats. Competition centers on the breadth of the product portfolio across film, gel, solution, and powder formats, clinical evidence and regulatory authorization for specific surgical indications, compatibility with laparoscopic and minimally invasive delivery, and price. The competitive landscape is evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with Baxter and Johnson & Johnson MedTech holding a substantial share through their film, solution, and cellulose barrier portfolios, alongside specialist vendors including Fziomed, Integra LifeSciences, Anika Therapeutics, PlantTec Medical, Biom'Up, MAST Biosurgery, Nordic Pharma, and Actamax Surgical Materials.
- Leading players: Baxter leads with its Seprafilm, Adept, and Coseal portfolio; Johnson & Johnson MedTech leads in oxidized regenerated cellulose with Interceed and Intercoat; Fziomed leads in dual-polymer gel and spray barriers with Oxiplex and SprayShield; and Integra LifeSciences leads in collagen-based dural adhesion barriers with DuraGen Plus.
- Geographic reach: Baxter and Johnson & Johnson MedTech operate global commercial and regulatory organizations, while specialist vendors including PlantTec Medical, Biom'Up, and Nordic Pharma maintain more concentrated footprints centered on Europe.
- Product portfolio strength: Competitive advantage rests on the breadth across film, gel, solution, and powder and spray formats, and on the range of surgical specialties addressed, from gynecological and abdominal surgery to cardiovascular and neurological surgery.
- Pipeline strength: Development is concentrated in laparoscopic-compatible gel and spray delivery, multifunctional hemostasis and adhesion prevention products, and expanded indications such as Fziomed's 2025 authorization for lumbar spine pain reduction.
- Strategic partnerships: Collaboration spans distribution partnerships, exemplified by Nordic Pharma's distribution of Anika Therapeutics' Hyalobarrier across Europe, and clinical research collaborations with academic surgical centers.
- M&A activity: Consolidation has shaped the field, exemplified by Baxter's 2020 acquisition of the Seprafilm product family from Sanofi for USD 350 million and continued portfolio bolt-on activity among diversified surgical technology companies.
- Innovation focus: Innovation is concentrated in laparoscopic and minimally invasive-compatible delivery formats, multifunctional hemostasis and adhesion prevention products, and expanded procedure-specific indications supported by new clinical evidence.
- Regulatory standing: FDA premarket approval and de novo classification, CE marking, and alignment with surgical society guidance are decisive competitive credentials, with Fziomed's 2025 FDA authorization of Oxiplex for lumbar spine pain reduction representing a notable recent regulatory milestone.
Adhesion Barrier Market Recent Developmental Activities
- In November 2025, Fziomed initiated commercialization in the United States of Oxiplex gel following FDA marketing authorization for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Strategic significance: the authorization was the first FDA authorization specifically for this indication and broadened Fziomed's addressable market into spine surgery pain reduction.
- In 2020, Baxter completed its acquisition of the Seprafilm adhesion barrier product family and related assets from Sanofi for USD 350 million. Strategic significance: the acquisition brought a leading, globally distributed HA/CMC adhesion barrier franchise into Baxter's advanced surgery portfolio alongside its hemostat and sealant business.
Adhesion Barrier Market Segmentation
Adhesion Barrier Market Assessment by Product Type
- Film and Membrane Barriers
- Gel Barriers
- Solution and Liquid Barriers
- Powder and Spray Barriers
Adhesion Barrier Market Assessment by Material
- Hyaluronic Acid and Cellulose-Based Barriers
- Synthetic Polymer-Based Barriers
- Collagen-Based Barriers
- Starch and Polysaccharide-Based Barriers
Adhesion Barrier Market Assessment by Application
- Gynecological Surgery
- General and Abdominal Surgery
- Orthopedic and Spine Surgery
- Cardiovascular Surgery
- Neurological Surgery
- Urological Surgery
- Others
Adhesion Barrier Market Assessment by End-User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
Adhesion Barrier Market Assessment by Geography
- North America
- United States Adhesion Barrier Market Size in USD million (2023-2034)
- Canada Adhesion Barrier Market Size in USD million (2023-2034)
- Mexico Adhesion Barrier Market Size in USD million (2023-2034)
- Europe
- Germany Adhesion Barrier Market Size in USD million (2023-2034)
- United Kingdom Adhesion Barrier Market Size in USD million (2023-2034)
- France Adhesion Barrier Market Size in USD million (2023-2034)
- Italy Adhesion Barrier Market Size in USD million (2023-2034)
- Spain Adhesion Barrier Market Size in USD million (2023-2034)
- Rest of Europe Adhesion Barrier Market Size in USD million (2023-2034)
- Asia-Pacific
- China Adhesion Barrier Market Size in USD million (2023-2034)
- Japan Adhesion Barrier Market Size in USD million (2023-2034)
- India Adhesion Barrier Market Size in USD million (2023-2034)
- Australia Adhesion Barrier Market Size in USD million (2023-2034)
- South Korea Adhesion Barrier Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Adhesion Barrier Market Size in USD million (2023-2034)
- Rest of the World
- Middle East Adhesion Barrier Market Size in USD million (2023-2034)
- Africa Adhesion Barrier Market Size in USD million (2023-2034)
- South America Adhesion Barrier Market Size in USD million (2023-2034)
Key Takeaways from the Adhesion Barrier Market Report Study
- Market size analysis for the current adhesion barrier market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product and technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global adhesion barrier market.
- Various opportunities available for competitors in the adhesion barrier market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current adhesion barrier market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for adhesion barrier market growth in the future?
Target audience who can benefit from this adhesion barrier market report study
- Adhesion barrier and surgical device providers
- Research organizations and consulting companies
- Surgical, gynecological, and related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in adhesion barrier devices
- Various end-users who want to know more about the adhesion barrier market and the latest technological developments in the adhesion barrier market.
Frequently Asked Questions:
Q1. At what rate is the adhesion barrier market expected to grow?
The global adhesion barrier market is projected to grow at a compound annual growth rate of 6.9% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the adhesion barrier market?
The global adhesion barrier market was valued at USD 1.1 billion in 2025 and is projected to reach USD 2.0 billion by 2034.
Q3. Which region dominates the adhesion barrier market?
North America dominated the adhesion barrier market with a 41% share in 2025, driven by the concentration of leading vendors, high surgical volume, and advanced regulatory and reimbursement infrastructure. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by hospital modernization and rising surgical volumes across China, Japan, and India.
Q4. What are the key factors driving growth in the adhesion barrier market?
The principal drivers are the rising volume of abdominal, pelvic, gynecological, and spine surgeries; growing surgeon and patient awareness of adhesion-related morbidity and cost; the expanding clinical evidence base across hyaluronic acid, cellulose, synthetic polymer, and starch-based barrier technologies; the introduction of multifunctional hemostasis and adhesion prevention products; and the increasing adoption of minimally invasive surgical techniques.
Q5. Who are the major players in the adhesion barrier market?
The market is moderately consolidated and led by Baxter International Inc. and Medical Devices Business Services, Inc. (Johnson & Johnson MedTech), alongside Fziomed, Inc., Integra LifeSciences Holdings Corporation, Anika Therapeutics, Inc., PlantTec Medical GmbH, Biom'Up SA, MAST Biosurgery USA, Inc., Nordic Pharma, and Actamax Surgical Materials, LLC.
Table of Contents
1. Adhesion Barrier Market Introduction
- 1.1. Scope of the Report
- 1.2. Market Segmentation
- 1.3. Market Overview at a Glance
2. Adhesion Barrier Market Executive Summary
- 2.1. Key Highlights and Market Snapshot
3. Adhesion Barrier Market Key Factors Analysis
- 3.1. Market Drivers
- 3.1.1. Rising Volume of Abdominal, Pelvic, Gynecological, and Spine Surgeries
- 3.1.2. Growing Awareness of Adhesion-Related Morbidity and Cost
- 3.1.3. Expanding Clinical Evidence Base Across Barrier Technologies
- 3.1.4. Multifunctional Hemostasis and Adhesion Prevention Products
- 3.2. Market Restraints
- 3.2.1. Inconsistent Clinical Evidence and Product-Specific Safety Considerations
- 3.2.2. High Per-Unit Cost Relative to Standard Surgical Technique
- 3.2.3. Limited Routine Integration into Standard Surgical Protocols
- 3.3. Market Opportunities
- 3.3.1. Laparoscopic and Minimally Invasive-Compatible Delivery
- 3.3.2. Procedure-Specific Indication Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
6. Adhesion Barrier Market Porter's Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
7. Adhesion Barrier Market Assessment
- 7.1. By Product Type
- 7.1.1. Film and Membrane Barriers
- 7.1.2. Gel Barriers
- 7.1.3. Solution and Liquid Barriers
- 7.1.4. Powder and Spray Barriers
- 7.2. By Material
- 7.2.1. Hyaluronic Acid and Cellulose-Based Barriers
- 7.2.2. Synthetic Polymer-Based Barriers
- 7.2.3. Collagen-Based Barriers
- 7.2.4. Starch and Polysaccharide-Based Barriers
- 7.3. By Application
- 7.3.1. Gynecological Surgery
- 7.3.2. General and Abdominal Surgery
- 7.3.3. Orthopedic and Spine Surgery
- 7.3.4. Cardiovascular Surgery
- 7.3.5. Neurological Surgery
- 7.3.6. Urological Surgery
- 7.3.7. Others
- 7.4. By End-User
- 7.4.1. Hospitals
- 7.4.2. Ambulatory Surgical Centers
- 7.4.3. Specialty Clinics
- 7.4.4. Others
- 7.5. By Geography
- 7.5.1. North America
- 7.5.1.1. United States Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.1.2. Canada Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.1.3. Mexico Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2. Europe
- 7.5.2.1. Germany Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2.2. United Kingdom Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2.3. France Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2.4. Italy Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2.5. Spain Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.2.6. Rest of Europe Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3. Asia-Pacific
- 7.5.3.1. China Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3.2. Japan Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3.3. India Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3.4. Australia Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3.5. South Korea Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.3.6. Rest of Asia-Pacific Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.4. Rest of the World
- 7.5.4.1. Middle East Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.4.2. Africa Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.4.3. South America Adhesion Barrier Market Size in USD million (2023-2034)
- 7.5.1. North America
8. Adhesion Barrier Market Competitive Landscape
- 8.1. Competitive Analysis
- 8.2. Company Share Analysis (Premium Offering)
9. Adhesion Barrier Market Startup Funding and Investment Trends
10. Adhesion Barrier Market Company and Product Profiles
- 10.1. Baxter International Inc.
- 10.1.1. Company Overview
- 10.1.2. Company Snapshot
- 10.1.3. Financial Overview
- 10.1.4. Product Portfolio
- 10.1.5. Strategic Initiatives / Entropy
- 10.2. Fziomed, Inc.
- 10.2.1. Company Overview
- 10.2.2. Company Snapshot
- 10.2.3. Financial Overview
- 10.2.4. Product Portfolio
- 10.2.5. Strategic Initiatives / Entropy
- 10.3. Integra LifeSciences Holdings Corporation
- 10.3.1. Company Overview
- 10.3.2. Company Snapshot
- 10.3.3. Financial Overview
- 10.3.4. Product Portfolio
- 10.3.5. Strategic Initiatives / Entropy
- 10.4. Medical Devices Business Services, Inc. (Johnson & Johnson MedTech)
- 10.4.1. Company Overview
- 10.4.2. Company Snapshot
- 10.4.3. Financial Overview
- 10.4.4. Product Portfolio
- 10.4.5. Strategic Initiatives / Entropy
- 10.5. Anika Therapeutics, Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Snapshot
- 10.5.3. Financial Overview
- 10.5.4. Product Portfolio
- 10.5.5. Strategic Initiatives / Entropy
- 10.6. PlantTec Medical GmbH
- 10.6.1. Company Overview
- 10.6.2. Company Snapshot
- 10.6.3. Financial Overview
- 10.6.4. Product Portfolio
- 10.6.5. Strategic Initiatives / Entropy
- 10.7. Biom'Up SA
- 10.7.1. Company Overview
- 10.7.2. Company Snapshot
- 10.7.3. Financial Overview
- 10.7.4. Product Portfolio
- 10.7.5. Strategic Initiatives / Entropy
- 10.8. MAST Biosurgery USA, Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Snapshot
- 10.8.3. Financial Overview
- 10.8.4. Product Portfolio
- 10.8.5. Strategic Initiatives / Entropy
- 10.9. Nordic Pharma
- 10.9.1. Company Overview
- 10.9.2. Company Snapshot
- 10.9.3. Financial Overview
- 10.9.4. Product Portfolio
- 10.9.5. Strategic Initiatives / Entropy
- 10.10. Actamax Surgical Materials, LLC
- 10.10.1. Company Overview
- 10.10.2. Company Snapshot
- 10.10.3. Financial Overview
- 10.10.4. Product Portfolio
- 10.10.5. Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
